FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119716808> ?p ?o ?g. }

• W3119716808 endingPage "S788" @default.
• W3119716808 startingPage "S788" @default.
• W3119716808 abstract "Abstract Background Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with in vitro activity against Enterobacterales (Ent) and Pseudomonas aeruginosa (Psa) carrying Class A, C and some Class D β-lactamases. We examined the in vitro activity of CAZ-AVI and comparators against isolates collected in Latin America (LA) as part of the ATLAS surveillance program. Methods Non-duplicate isolates of Ent (n=8416) and Psa (n=2521) were collected in 10 countries in Central America (CAC; Costa Rica, Dominican Republic, Guatemala, Panama [2018-2019 only]) and South America (SA; Argentina, Brazil, Chile, Colombia, Mexico, Venezuela [2017-2019]). Susceptibility testing was performed by CLSI broth microdilution and values were interpreted using CLSI 2020 breakpoints. CAZ-AVI was tested at a fixed concentration of 4 µg/mL AVI. Isolates with meropenem (MEM) MICs ≥2 µg/mL (Ent) or ≥4 µg/mL (Psa) were screened for β-lactamase genes. Results CAZ-AVI demonstrated potent in vitro activity against Ent collected in LA overall and in the CAC and SA subregions (95-99% susceptible (S)) that was comparable to or exceeded the activity of comparators including MEM, amikacin (AMK) and tigecycline (TGC) (Table). CAZ-AVI retained good activity against MEM non-susceptible (NS) Ent collected in SA (82% S; 6.9% of collected isolates) but activity was reduced against MEM-NS Ent from CAC (10% S; 5.7% of collected isolates), which included a high proportion of isolates carrying NDM-type metallo-β-lactamases (MBL). Among Psa, CAZ-AVI showed greater activity than the tested comparators against both all (86-92% S) and MEM-NS (61-66% S) isolates collected in LA overall and in the two subregions. Table Conclusion CAZ-AVI showed potent in vitro activity against Ent and Psa collected from patients in the CAC and SA subregions of LA. Activity was also good against MEM-NS isolates from SA but was reduced against MEM-NS Ent from CAC that included a high proportion of MBL-positive isolates. The regional and country prevalence of different carbapenem-resistance mechanisms must be considered when evaluating treatment options; however, CAZ-AVI could provide a valuable therapeutic option for treatment of infections caused by Ent and Psa in LA. Disclosures Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Maria Lavinea Valente, MD, Pfizer Brazil (Employee) Elkin Lemos, MD, PhD, Pfizer Columbia (Employee) Monique Baudrit, MD, MSc, Pfizer Costa Rica (Employee) Alvaro Quintana, MD MSc, Pfizer, Inc. (Employee) Paurus Irani, MD, Pfizer United Kingdom (Employee) Greg Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
• W3119716808 created "2021-01-18" @default.
• W3119716808 creator A5015415938 @default.
• W3119716808 creator A5023169124 @default.
• W3119716808 creator A5038009031 @default.
• W3119716808 creator A5064433248 @default.
• W3119716808 creator A5066677972 @default.
• W3119716808 creator A5068555715 @default.
• W3119716808 creator A5083517680 @default.
• W3119716808 creator A5088626519 @default.
• W3119716808 date "2020-10-01" @default.
• W3119716808 modified "2023-09-27" @default.
• W3119716808 title "1580. <i>In Vitro</i> Activity of Ceftazidime-Avibactam Against Enterobacterales and <i>Pseudomonas aeruginosa</i> Collected in Latin America as part of the ATLAS Global Surveillance Program, 2017-2019" @default.
• W3119716808 doi "https://doi.org/10.1093/ofid/ofaa439.1760" @default.
• W3119716808 hasPublicationYear "2020" @default.
• W3119716808 type Work @default.
• W3119716808 sameAs 3119716808 @default.
• W3119716808 citedByCount "1" @default.
• W3119716808 countsByYear W31197168082022 @default.
• W3119716808 crossrefType "journal-article" @default.
• W3119716808 hasAuthorship W3119716808A5015415938 @default.
• W3119716808 hasAuthorship W3119716808A5023169124 @default.
• W3119716808 hasAuthorship W3119716808A5038009031 @default.
• W3119716808 hasAuthorship W3119716808A5064433248 @default.
• W3119716808 hasAuthorship W3119716808A5066677972 @default.
• W3119716808 hasAuthorship W3119716808A5068555715 @default.
• W3119716808 hasAuthorship W3119716808A5083517680 @default.
• W3119716808 hasAuthorship W3119716808A5088626519 @default.
• W3119716808 hasBestOaLocation W31197168081 @default.
• W3119716808 hasConcept C104317684 @default.
• W3119716808 hasConcept C176947019 @default.
• W3119716808 hasConcept C2775933652 @default.
• W3119716808 hasConcept C2776968632 @default.
• W3119716808 hasConcept C2777027569 @default.
• W3119716808 hasConcept C2777402170 @default.
• W3119716808 hasConcept C2777406300 @default.
• W3119716808 hasConcept C2777637488 @default.
• W3119716808 hasConcept C2778910516 @default.
• W3119716808 hasConcept C2779375183 @default.
• W3119716808 hasConcept C2780950330 @default.
• W3119716808 hasConcept C501593827 @default.
• W3119716808 hasConcept C523546767 @default.
• W3119716808 hasConcept C54355233 @default.
• W3119716808 hasConcept C547475151 @default.
• W3119716808 hasConcept C55493867 @default.
• W3119716808 hasConcept C556039675 @default.
• W3119716808 hasConcept C71924100 @default.
• W3119716808 hasConcept C86803240 @default.
• W3119716808 hasConcept C89423630 @default.
• W3119716808 hasConcept C94665300 @default.
• W3119716808 hasConceptScore W3119716808C104317684 @default.
• W3119716808 hasConceptScore W3119716808C176947019 @default.
• W3119716808 hasConceptScore W3119716808C2775933652 @default.
• W3119716808 hasConceptScore W3119716808C2776968632 @default.
• W3119716808 hasConceptScore W3119716808C2777027569 @default.
• W3119716808 hasConceptScore W3119716808C2777402170 @default.
• W3119716808 hasConceptScore W3119716808C2777406300 @default.
• W3119716808 hasConceptScore W3119716808C2777637488 @default.
• W3119716808 hasConceptScore W3119716808C2778910516 @default.
• W3119716808 hasConceptScore W3119716808C2779375183 @default.
• W3119716808 hasConceptScore W3119716808C2780950330 @default.
• W3119716808 hasConceptScore W3119716808C501593827 @default.
• W3119716808 hasConceptScore W3119716808C523546767 @default.
• W3119716808 hasConceptScore W3119716808C54355233 @default.
• W3119716808 hasConceptScore W3119716808C547475151 @default.
• W3119716808 hasConceptScore W3119716808C55493867 @default.
• W3119716808 hasConceptScore W3119716808C556039675 @default.
• W3119716808 hasConceptScore W3119716808C71924100 @default.
• W3119716808 hasConceptScore W3119716808C86803240 @default.
• W3119716808 hasConceptScore W3119716808C89423630 @default.
• W3119716808 hasConceptScore W3119716808C94665300 @default.
• W3119716808 hasIssue "Supplement_1" @default.
• W3119716808 hasLocation W31197168081 @default.
• W3119716808 hasLocation W31197168082 @default.
• W3119716808 hasLocation W31197168083 @default.
• W3119716808 hasOpenAccess W3119716808 @default.
• W3119716808 hasPrimaryLocation W31197168081 @default.
• W3119716808 hasRelatedWork W2163292670 @default.
• W3119716808 hasRelatedWork W2345934860 @default.
• W3119716808 hasRelatedWork W2790249024 @default.
• W3119716808 hasRelatedWork W2990287059 @default.
• W3119716808 hasRelatedWork W3118395702 @default.
• W3119716808 hasRelatedWork W3118439655 @default.
• W3119716808 hasRelatedWork W3119311612 @default.
• W3119716808 hasRelatedWork W3119716808 @default.
• W3119716808 hasRelatedWork W4285085606 @default.
• W3119716808 hasRelatedWork W4310707367 @default.
• W3119716808 hasVolume "7" @default.
• W3119716808 isParatext "false" @default.
• W3119716808 isRetracted "false" @default.
• W3119716808 magId "3119716808" @default.
• W3119716808 workType "article" @default.